### 1 A randomized controlled trial of postbiotic administration during antibiotic treatment

#### 2 increases microbiome diversity and enriches health associated taxa.

- Jonas Schluter<sup>1-4\*</sup>, Fanny Matheis<sup>1</sup>, Wataru Ebina<sup>1,3</sup>, William Jogia<sup>1,2</sup>, Alexis P. Sullivan<sup>1</sup>, Kelly
- 4 Gordon<sup>4</sup>, Elbert Fanega de la Cruz<sup>5</sup>, Mary E Victory-Hays<sup>5</sup>, Mary Joan Heinly<sup>5</sup>, Catherine S.
- 5 Diefenbach<sup>3</sup>, Jonathan U. Peled<sup>4,6,7</sup>, Kevin R. Foster<sup>4,8,9</sup>, Aubrey Levitt<sup>4</sup>, Eric McLaughlin<sup>4,6</sup>
- 6
- 7 <sup>1</sup> Institute for Systems Genetics, New York University Grossman School of Medicine, New York,
  - 8 NY, USA
  - <sup>9</sup> <sup>2</sup> Department of Microbiology, New York University Grossman School of Medicine, New York,
- 10 NY, USA
- <sup>3</sup> Laura and Isaac Perlmutter Cancer Center, New York University Grossman School of Medicine,
- 12 New York, NY, USA
- <sup>4</sup> Postbiotics Plus Research, Houston, TX, USA
- <sup>5</sup> Patients Emergency Room & Hospital 10133 I-10, Baytown, TX, USA
- <sup>6</sup> Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan
- 16 Kettering Cancer Center, New York, NY, USA
- 17 <sup>7</sup> Weill Cornell Medical College, New York, NY, USA
- <sup>8</sup> Department of Biology, University of Oxford; Oxford, UK
- <sup>9</sup> Department of Biochemistry, University of Oxford; Oxford, UK
- 20 \*) correspondence: jonas.schluter@nyulangone.org
- 21
- Postbiotic administration during antibiotic treatment increases bacterial alpha diversity
- Characteristic bacterial signatures are associated with postbiotic administration
- Health-associated taxa are enriched and disease-associated taxa are reduced by postbiotic
   treatment
- 26
- 27

#### 28 Author contributions

- AL and EM conceived of the trial, with support by JS. AL, EM, oversaw and conducted the trial,
- 30 with support by KG, EFC, MEVH, and MJH. JS conducted the analyses and wrote the
- 31 manuscript with support by CSD, WE, FM, APS, and JUP. JS, FM, WE, WJ, KRF and JUP
- 32 analyzed and interpreted the results. All authors read and commented on the manuscript.
- 33

# 34 Acknowledgements

- JS reports funding from the National Institutes of Health (NIH) grants DP2 AI164318-01, and
- 36 R01CA269617. FM is supported by a Helen Hay Whitney Fellowship. JUP reports funding from
- NHLBI NIH Award K08HL143189, the MSKCC Cancer Center Core Grant NCI P30 CA008748.
- 38 We would like to thank Kate Markey for comments and discussion of the manuscript.
- 39

## 40 Conflict of Interest Disclosure

- 41 AL is CEO of Postbiotics Plus Research. AL and JS are co-founders of Postbiotics Plus Research.
- 42 AL, JS, EL, KRF, JUP hold equity in Postbiotics Plus Research. JUP reports research funding,
- 43 intellectual property fees, and travel reimbursement from Seres Therapeutics, and consulting fees
- 44 from DaVolterra, CSL Behring, and from MaaT Pharma. JUP has filed intellectual property
- 45 applications related to the microbiome (reference numbers #62/843,849, #62/977,908, and
- 46 #15/756,845). Memorial Sloan Kettering Cancer Center (MSK) has financial interests relative to
- 47 Seres Therapeutics. AL and JS have filed intellectual property applications related to the
- 48 microbiome (reference numbers #63/299,607). JUP and KRF serve on an Advisory board of
- 49 Postbiotics Plus Research. JS serves on an Advisory board and holds equity of Jona Health.

#### 50 Abstract

Antibiotic-induced microbiome injury, defined as a reduction of ecological diversity and obligate 51 52 anaerobe taxa, is associated with negative health outcomes in hospitalized patients, and healthy individuals who received antibiotics in the past are at higher risk for autoimmune diseases. No 53 interventions are currently available that effectively target the microbial ecosystem in the gut to 54 prevent this negative collateral damage of antibiotics. Here, we present the results from a single-55 center, randomized placebo-controlled trial involving 32 patients who received an oral, 56 fermentation-derived postbiotic alongside oral antibiotic therapy for gastrointestinal (GI)-57 unrelated infections. Postbiotics comprise complex mixtures of metabolites produced by bacteria 58 during fermentation and other processes, which can mediate microbial ecology. Bacterial 59 ecosystem alpha diversity, quantified by the inverse Simpson index, during the end of the 60 antibiotic course was significantly higher (+40%) across the 16 postbiotic-treated patients 61 compared with the 16 patients who received a placebo, and the postbiotic was well-tolerated. 62 Secondary analyses of 157 stool samples collected longitudinally revealed that the increased 63 diversity was driven by enrichment in health-associated microbial genera: obligate anaerobe 64 65 Firmicutes, in particular taxa belonging to the Lachnospiraceae family, were higher in treated patients; conversely, Escherichia/Shigella abundances, which comprise pathobionts and 66 antimicrobial-resistant strains, were reduced in postbiotic-treated patients at the end of their 67 antibiotic course and up to 10 days later. Taken together, these results indicate that postbiotic co-68 69 administration during antibiotic therapy could support a health-associated gut microbiome community and may reduce antibiotic-induced microbiome injury. 70

#### 72 Introduction / Background

Antibiotic therapy is the most effective treatment to fight bacterial infections and indispensable 73 74 in modern medicine; it can cure mild disease and save lives in severe cases of bacteremia<sup>1</sup>, organ invasion and sepsis<sup>2</sup>. Recently, however, evidence has accumulated that oral antibiotic treatment 75 may collaterally injure the human microbiome<sup>3-11</sup>. Antibiotics may interfere with commensal 76 bacterial growth, or can kill health-associated bacterial populations <sup>3,9</sup>, a phenomenon that may 77 have been vastly underestimated<sup>3</sup>. Such disruption of the commensal microbial ecosystem can 78 persist for months following antibiotic exposure<sup>7</sup> and is seen in otherwise healthy individuals<sup>12</sup> 79 as well as severely immunocompromised, hospitalized patients who, in some instances, lose 80 most of the normally resident bacteria $^{8-11}$ . Clearance of the normal flora can enable persistent 81 colonization by pathogens, e.g., Clostridioides difficile, and cause recurrent, difficult-to-cure, 82 infections<sup>13,14</sup>. 83

Antibiotic-induced interference with bacterial reproduction and killing of gut bacterial 84 populations lead to shifts in the gut microbiome ecosystem that can be characterized by a decline 85 in alpha diversity<sup>9,10,15</sup>. Alpha diversity metrics are summary measures quantifying the ecological 86 87 composition of a microbiome sample; they may capture the number of taxonomic groups (e.g. more taxa increase diversity) and their abundance distributions (e.g. more evenly distributed 88 taxon abundances increase diversity)<sup>16</sup>. Therefore, they have been used to quantify microbiome 89 injury at the ecosystem level<sup>17</sup>. Notably, antibiotic use and loss of bacterial microbiome alpha 90 91 diversity have been associated with health risks, including higher mortality in hematopoietic stem cell transplantation<sup>18,19</sup>, translocation of microorganisms from the gut into the bloodstream 92 (often resulting in bacteremia and sepsis) in immunocompromised patient populations<sup>10,11,15,20,21</sup>, 93 increased risk for inflammatory bowel disease<sup>22</sup> and severity of autoimmune and allergic 94 diseases<sup>23–27</sup>. Furthermore, loss of bacterial diversity can affect cross-kingdom interactions: 95 depletion of bacterial competitors may allow for fungal species to expand<sup>28</sup>, and fungal 96 expansions were associated with increased risk of fungal bloodstream infections in cancer 97 patients<sup>15</sup> as well as fungal urogenital infections in otherwise healthy women<sup>29</sup>. Recently, 98 antibiotic exposure has been associated with worse response to cancer immunotherapies<sup>30–34</sup>, and 99 100 direct links between perturbation of the microbiome and human immune system modulation are emerging<sup>35–37</sup>. 101

102 A diverse microbiome, predominantly populated by obligate anaerobe taxa, is thus associated with good health. As a result, means to restore the microbiome following antibiotic 103 104 exposure are much sought after. Autologous fecal microbiota transplantation (auto-FMT) can recover antibiotic-depleted bacteria using fecal materials harvested and stored prior to 105 treatment<sup>38</sup>. Heterologous FMTs with material from healthy donors (allo-FMT) have shown 106 promising results in improving inflammatory bowel disease<sup>39</sup>, response to immune therapy<sup>40</sup>, and 107 successfully reduced C. difficile abundances and recurrence<sup>41,42</sup>. FMTs, however, come with 108 risks<sup>43</sup>: antimicrobial-resistant strains are prevalent in the microbiome<sup>11</sup> and can sometimes cause 109 life-threatening complications during FMT<sup>44</sup>. Furthermore, matching donor to recipients for 110 optimal engraftment remains an unsolved challenge<sup>45</sup>. Nevertheless, recently, the U.S. Food and 111 Drug Administration has approved two FMT-based therapies: a rectally administered single dose 112 of prepared stool from healthy donors and a fecal microbiota-based oral treatment, both to 113 prevent the recurrence of C. difficile infection<sup>46,47</sup>. In addition to large community transfers via 114 FMT, administration of selected live microbial species, termed probiotics, have been established, 115 albeit with conflicting data on efficacy  $^{48,49}$ , and variable recipient colonization  $^{50,51}$ . Whilst 116 probiotics are generally assumed to be safe, their use has been associated with adverse 117 outcomes<sup>48</sup>, such as bacteremia<sup>52</sup>, fungemia<sup>53</sup>, and bowel ischemia<sup>49</sup> especially in 118 immunocompromised and critically ill patients. Facilitation of probiotic colonization following 119 antibiotic-induced depletion of recipient commensals can also lead to persistent dysbiosis and 120 delay recovery of the pretreatment microbiome<sup>54</sup>. These shortcomings of probiotics highlight the 121 potential benefit of modulating resident commensal microbial ecology without the addition of 122 123 new microbial strains and species towards safe and robust microbe-targeted therapies. Aside from live therapeutics, one potential alternative is the use of prebiotics. These are substances 124 125 intended to provide nutrients to specific, desired microbial populations, and have recently been shown to have some effects on microbiome communities<sup>37</sup>. Surprisingly, however, a beneficial, 126 anti-inflammatory effect was observed resulting from increased consumption of fermented 127 foods<sup>37</sup>. Thus, products of fermentation may offer a novel therapeutic avenue to manipulate the 128 microbiome. 129

As such, an emerging alternative to live therapeutics, which we explore here, is the use of
postbiotics. Postbiotics is an umbrella term that comprises complex mixtures of metabolites

produced by bacteria for example during fermentation, as well as cell wall components and other
dead cell components (as well as some potentially viable cells<sup>55</sup>).

134 Emerging pre-clinical and clinical studies indicate health-beneficial effects of postbiotics<sup>37,56,57</sup>. Thus, postbiotics may offer a safe novel therapeutic avenue to target the 135 microbiome. In particular, we hypothesize that reduction of antibiotic-induced microbiome 136 damage could prevent antibiotic-induced impairment of novel immunotherapies and health 137 sequalae<sup>30,58</sup>. However, it is not yet known if postbiotics can reduce microbiome diversity loss 138 during antibiotic treatment. Here, we describe the results of a single-center randomized 139 controlled trial to assess the ability of a fermentation-derived postbiotic to prevent antibiotic-140 induced injury to the commensal microbiome in patients receiving oral antibiotics. Following a 141 course of antibiotics, we collected stool samples at five timepoints and profiled the composition 142 of bacterial populations. Our data indicate that treatment with a postbiotic during a course of oral 143 antibiotics supports gut microbial ecosystem stability and health-associated taxa. 144

145

## 146 **Results**

#### 147 Overview of study design and intervention

A single-center, randomized placebo-controlled trial of postbiotic treatment (T, n=16) versus 148 149 placebo (C, n=16) was conducted to measure bacterial alpha diversity as a primary endpoint at the end and directly after finishing a course of oral antibiotics. The goal was to determine 150 151 feasibility, safety, and a preliminary efficacy assessment of the procedure for prevention of medication-induced injury of the gut microbiota (Study title: Randomized controlled trial of 152 153 PBP-GP-22 to affect microbiome composition; https://www.isrctn.com; trial registration ISRCTN30327931). Otherwise healthy ambulatory adult patients (Table 1) presenting to a single 154 155 clinical site in Houston, Texas, between 05 and 06/2018 for non-gastrointestinal infections were recruited. After giving informed consent, patients were provided with take-home stool sample 156 collection kits, a supply of a commercially available probiotic, and a supply of the placebo 157 (control, C) or postbiotic (treatment, T) to be taken during and ten days beyond the antibiotic 158 course (administered antibiotics are listed in Table S1) along with the commercial probiotic and 159 their standard-therapy antibiotic (Figure 1, S1, CONSORT report<sup>59</sup>). We chose to include the 160 probiotic background, which included six strains of Lactobacillus and Bifidobacterium, because 161 162 it was the standard recommendation by the participating physicians when administering

antibiotics. Moreover, by including an existing treatment in our study, our design represented a
relatively stringent test of the ability of a postbiotic to further improve outcomes. A total of 157
stool samples were collected longitudinally, for up to five timepoints (S1-S5) relative to the end
of a full course of prescribed antibiotics per patient (Figure 1A).

167 It was hypothesized that microbiome injury would be maximal at the end of a completed 168 course of antibiotics. Therefore, the primary endpoint was set as bacterial alpha diversity,

- 169 measured by the inverse Simpson index on three timepoints at the end of the antibiotic course: on
- the day prior to finishing the antibiotic treatment (S1), directly after completing the antibiotic (S2)
- and one day thereafter (S3). Among patients who entered the study, stool sampling rates were

172 high, with only a single sample from S3 missing in the final analysis set (FAS, target participant

173 number: 25, FAS: 32, Figure 1B). Patients were given a phone number to call to report any side

174 effects, and were contacted via text messages prior to fecal sample collection; there were no

- 175 grade 3 or higher side effects reported (Table S2).
- 176

	Characteristic	Control	Treatment	<i>p</i> value
178	calculations indicated.			
177	Table 1: Patient characteristics and ind	lications by treatr	nent arm, with statist	ical tests for p value

Age		39, [20,60]	45, [20, 64]	0.95 (t-test)
Sex	Female	10	8	0.72 (Chi2)
	Male	6	8	
Disease				
	Sinusitis	5	3	
	Cellulitis	2	1	
	Kidney infection/UTI	1	0	
	Abscess	1	0	
	Ear infection	2	0	
	Cyst	1	0	
	Pharyngitis/Strep	1	6	
	Bronchitis	1	2	
	Laceration	0	1	
	Toothache	0	1	
	Other	2	2	

# 180 Bacterial alpha diversity at the end of an antibiotic course is high in patients receiving the

## 181 **postbiotic**

182 Microbiome profiling by amplification and sequencing of the V4 region of the 16S rRNA gene was performed on DNA collected from 157 samples. Bacterial alpha diversity measured at the 183 end of the antibiotic treatment (S2) was significantly higher in postbiotic-treated patients 184 185 compared with placebo recipients for different alpha diversity metrics (Figure 1C, Shannon: +24%, p=0.046; Simpson: +19%, p=0.048; inverse Simpson: +43%, p=0.056, t-test). Time series 186 analysis<sup>38</sup> of longitudinally collected samples (Figure S2) showed that postbiotic-treated patients 187 had significantly higher alpha diversity during the end phase of their antibiotic treatment (Figure 188 **1D**, p=0.037, linear mixed effects model). Together, these results indicate that addition of this 189 postbiotic to an orally-administered antibiotic course is clinically feasible, well-tolerated, and 190 191 significantly increased gut microbial alpha-diversity.

192

### 193 **Postbiotic treatment is associated with characteristic bacterial signatures**

We next sought to analyze differences between microbial ecosystems in treated vs control 194 195 patients at a higher resolution than resolved by alpha diversity metrics. For this, we first visualized the individual patients' compositional time courses by plotting the relative abundances 196 197 of the most abundant bacterial families (Figure 2A), which indicated compositional variation across patients and changes over time in several individuals. To analyze compositional 198 199 variability, we next performed a principal coordinate analysis (PCoA) on sample-by-sample Bray-Curtis distances calculated on operational taxonomic units' (OTUs) relative abundances 200 201 (Figure 2B-E). Samples from patients of either sex localized across the projected bacterial compositions (Figure 2B). In most samples, obligate anaerobe Bacteroidetes taxa represented 202 203 the most abundant bacterial families (Figure 2C), whereas samples from both experimental arms 204 contained only low relative abundances of the genera corresponding to the probiotics taken by all patients (median relative genus abundance: Bifidobacterium [C: 3.9e-4, T:4.3e-4], Lactobacillus 205 [C: 1e-4, T: 0.9e-4]; Figure S3). Consecutive samples from the same patient tended to localize 206 near one another, with significantly lower intra- than inter-patient variability during the transition 207 208 from antibiotics into the post-antibiotic period (Figure 2D), even though the observed microbiome dynamics in several patients spanned wide regions of the compositional space. 209 210 While samples from treated and control patients localized across the PCoA space, a statistical

analysis indicated that the samples from treated patients varied consistently in their composition

from those observed in control patient samples (Figure 2E), which suggested characteristic gut

213 bacterial communities in treated patients.

214

# Postbiotic treatment is associated with an enrichment in health- and a reduction in diseaseassociated taxa

To analyze which taxa were consistently higher in treated patients or lower alongside the reduced diversity in control patients, we compared the relative abundance profiles between the two patient groups directly after finishing the antibiotic course (S2), and over time (S1-S3). To account for the compositional nature of 16S relative abundance data, we calculated the centeredlog ratio (CLR) transformation of relative taxon abundances across all samples. To reduce sparsity of the OTU-level data, we aggregated relative abundances at the phylum, family or genus levels prior to CLR transformation.

224 Statistical comparison of the CLR-transformed phylum relative abundances directly after finishing the antibiotic course (S2) revealed a significantly higher abundance of Firmicutes 225 226 among treated patients (Figure 3A, p-value=0.002, q-value<0.05, 0.1 FDR). At higher taxonomic resolutions, we analyzed the 10 most abundant bacterial families and 20 most 227 228 abundant genera after CLR-transformation: Lachnospiraceae and Bacteroidaceae (family-level analysis), and Roseburia, Bacteroides, and Ruminiclostridium 5 (genus-level analysis) were 229 230 enriched in treated patients at S2 (Figure 3B, C). However, the observed taxon enrichments, while significant in univariate analyses, did not remain significant after correcting for multiple 231 232 hypotheses, with the exception of the observed enrichment of Lachnospiraceae in treated patients 233 (univariate p-value=0.004, q<0.05, 0.1 FDR), which remained significant.

234 We next analyzed CLR-transformed genus abundances in samples S1 to S3. Using a more stringent false discovery rate (0.05 FDR) as well as a minimal effect size cutoff (0.5), 235 revealed several genera significantly enriched in treated patients, including Anaerostipes, 236 Eubacterium coprostanoligenes group, Fusicantenibacter, and Roseburia, and significantly 237 reduced genera in treated patients, including Fusobacterium and Escherichia/Shigella (Figure 238 239 **3D**, **S4**). We tested the 13 differentially abundant genera in a mixed effects model (Figure 3E), which confirmed the associations found in the univariate pooled analysis screen (Figure 3D). 240 241 Furthermore, consistent with these results, we found similar associations when performing

multivariate analyses using regularized regression approaches (Figure S5), which confirmed a 242 trend towards enrichment of commensal obligate anaerobe genera among treated patients. We 243 244 also compared the abundances of anaerobe taxa discussed as immunomodulatory in the context of cancer therapies<sup>31,32,35</sup>, and found higher abundances of Lachnospiraceae, which comprise 245 Faecalibacterium, Ruminococcaceae, which comprise Ruminococcus, and Verrucomicrobiaceae, 246 which comprise Akkermansia, in treated patients (Figure S6). Interestingly, this enrichment of 247 health-associated anaerobe taxa and concurrent lower levels of facultative anaerobe, pathobiont-248 comprising taxa in treated patients appeared to persist beyond the immediate end of the antibiotic 249 exposure (Figure S7), even though alpha diversity in control patients had already approached 250 similar levels to treated patients ten days after the antibiotic course ended (Figure S8). In 251 particular, facultative-anaerobe gamma-proteobacteria of the Escherichia/Shigella genus were 252 reduced in treated patients even 10 days after finishing their antibiotic course (Figure S7B). 253 Taken together, these results support an enrichment of a health-associated microbial community 254 in patients treated with a postbiotic during their antibiotic course. 255

256

#### 257 Discussion

We here presented results from a single center randomized placebo-controlled trial to assess the 258 protective effect of a postbiotic adjuvant on microbiome diversity during antibiotic therapy. 259 Collateral injury to the resident gut microbiota caused by antibiotics has been described as a loss 260 of bacterial ecosystem diversity<sup>18</sup>, loss of commensal microbial taxa<sup>9,15</sup>, and increase of 261 pathobionts, which can comprise antibiotic-resistant species<sup>11</sup>. The enrolled patients were 262 263 ambulatory and treated with oral antibiotics for non-gastrointestinal infections. Thus, the patient cohort studied here were at a lower risk for microbiome injury-induced complications than for 264 example blood cancer patients<sup>11,15,18</sup>. Among those higher-risk patients, overall survival is 265 statistically associated with antibiotic induced loss of diversity<sup>18</sup>, and response to chimeric 266 antigen receptor T cell therapy is negatively associated with antibiotic exposure<sup>30,34,58</sup>. In 267 hospitalized COVID-19 patients, another high-risk patient group, a combination of antibiotics 268 and viral infection were found to predispose patients to gut born bacteremia<sup>10</sup>. Nevertheless, 269 270 even in otherwise healthy individuals such as were studied here, post-antibiotic complications such as diarrhoea<sup>60</sup>, post-antibiotic *Clostridioides difficile* infection<sup>61</sup>, or vaginal candidiasis<sup>62</sup> are 271 272 common, and selection for antimicrobial resistant strains (AMR) in the gut microbiome may

pose a potential health risk during future therapies. Therefore, reducing the negative collateral
impact of antibiotics on the microbiome constitutes a critical unmet need.

275 Our results indicate that microbiome injury is lower when co-administering an oral postbiotic alongside the oral antibiotic: bacterial alpha diversity was significantly higher at the 276 end of an antibiotic course in patients who received the postbiotic instead of the placebo, and this 277 increased diversity was driven by commensal taxa. Health-associated obligate anaerobe 278 organisms were higher in treated patients: Fusicantenibacter, which is depleted in rheumatoid 279 arthritis patients<sup>63</sup>, short-chain fatty acid-producing *Roseburia*, one of the most abundant genera 280 in the healthy gut microbiome<sup>64</sup>, the butyrogenic Anaerostipes genus, which comprises lactate-281 consuming species<sup>65</sup>, and the *Eubacterium coprostanoligenes* group, which has been 282 hypothesized to be involved in beneficial fat metabolism by reducing cholesterol<sup>66</sup>. Conversely, 283 Escherichia/Shigella, a genus of gram negative facultative anaerobe species that comprise 284 multiple antibiotic-resistant strains and pathobionts which can cause secondary bacteremia when 285 translocating across a weakened gut barrier<sup>10,11</sup>, were significantly lower in treated than in 286 control patients. Interesting, we also observed that *Fusobacterium*, an obligate anaerobe taxon, 287 288 was significantly lower in treated patients. Its predominant species, F. nucleatum, is commonly found in the oral microbiome and associated with the development of colorectal cancer when 289 abundant in the gut<sup>67,68</sup>. It is plausible that the higher diversity of commensal gut bacteria in 290 treated patients improved colonization resistance and reduced gut colonization of F. nucleatum 291 292 when swallowed. Furthermore, the higher diversity of commensal organisms may have suppressed the opportunistic expansion of *Escherichia/Shigella* observed in control patients via 293 competitive exclusion<sup>11,69–71</sup>. 294

Limitations of the study include that both treatment arms received a commercial probiotic; 295 296 however, low abundances of the taxa from the probiotics in both treatment arms indicated that this had no influence on the diversity differences observed between treatment arms. Nevertheless, 297 future studies are warranted to validate the efficacy of the oral postbiotic outside of the context 298 of concurrent probiotic administration. Furthermore, due to the enrollment at an urgent care 299 300 clinic where patients were instructed to start their treatment immediately, no baseline stool 301 sample prior to antibiotics was collected. However, we speculate that the impact of antibiotics on the microbiome are maximal at the end of an antibiotic course, and that thus the increase in 302 303 diversity observed among treated patients could reflect protection of the commensal microbiome.

This is a plausible scenario because of the enrichment of commensal taxa in the microbiome of patients treated with the postbiotic, which did not include these taxa. The study results, while significant and of considerable magnitude, are based on a small cohort and the direct impact on patients' health was not assessed in this trial, which focused on microbiome diversity as a primary outcome. Additional studies are now warranted to validate the herein described beneficial impact of postbiotic treatment on the microbiome and assess if the stabilization of the microbiome translates into a patient health benefit.

Recently, consumption of fermented plant-based foods were described to have a 311 beneficial effect on the microbiome and immune system<sup>37</sup>. The postbiotic under investigation is a 312 complex biologic product derived from the fermentation of medicinal plants by generally 313 regarded as safe (GRAS) bacterial species. Unlike in fermented foods, manufacturing of 314 postbiotics generally includes a dedicated inactivation step that reduces live cell counts<sup>55</sup>, and 315 therefore, they are assumed to have a generally favorable safety profile over live therapeutic 316 based approaches. For the manufacturing of the postbiotic used in this trial, a fermentation 317 process by specific species of Lactobacillus and Bifidobacterium was used, which represent 318 major taxa commonly present during the assembly of the infant microbiome<sup>72</sup>. While the 319 mechanism of action of the observed protection of gut microbiome diversity is not fully 320 321 understood, we hypothesize that bacterial metabolites of these species, their products of secondary metabolism and signaling molecules may support or elicit competitive responses 322 within resident members of the commensal adult microbiome, which have evolved to 323 ecologically succeed early colonizers of the gut microbiome<sup>73</sup>, increasing their resilience to 324 external perturbations<sup>74</sup>. 325

In conclusion, here we have presented evidence that co-administering a fermentation derived postbiotic can increase gut microbiome diversity during antibiotic treatments. The increased diversity was associated with higher abundances of health-associated bacterial taxa, while genera comprising pathobionts were lower among postbiotic treated patients.

#### 330 Methods

#### 331 Human subjects

Table 1 reports metadata, including age and sex, corresponding to the 32 healthy adult subjects
enrolled in a single site double-blind randomized controlled study (trial registration ID:
ISRCTN30327931). This study was reviewed and approved by New England Institutional
Review Board, an independent IRB located in Needham, MA. All subjects were provided with
an explanation of the study and gave informed consent in writing prior to the start of their
participation in the study.

338

#### 339 Human subject study methods

Fifty-one ambulatory adult subjects were initially evaluated for eligibility (see inclusion and 340 exclusion criteria used to evaluate subject suitability listed below), one was not eligible. Fifty of 341 the subjects were then enrolled in a single site double-blind interventional study with a 342 randomized-controlled design to test the hypothesis that patients receiving an oral postbiotic 343 would present with higher bacterial alpha diversity, measured by the inverse Simpson index, 344 345 during three time points at the end of an antibiotic course than patients receiving a placebo control. Analyzed timepoints were: the final day of antibiotics, the first day after completing the 346 347 antibiotics course, and the second day after completing the antibiotics course. Analysis was performed by time series analysis that accounts for repeated measurements and uses time as 348 categorical predictors, as done before<sup>38,75</sup>. This study was reviewed and approved by New 349 England Institutional Review Board, an independent IRB located in Needham, MA. Eligibility 350 351 for enrollment was determined by the following inclusion and exclusion criteria:

352

353 Inclusion criteria:

- Otherwise healthy adults with a body mass index (BMI) (18-28 kg/m<sup>2</sup>)
- 355

• Patients are prescribed a course of antibiotics with a duration of at least 5 days

356 357

• Patients are willing to cease taking any other supplements

358 Exclusion criteria:

•

patients suffering from gut related illness (regular and severe constipation, diarrhea,
 inflammatory bowel disorder or inflammatory bowel disease).

Patients have not had another course of antibiotics in the past 6 months

- patients who usually experience severe diarrhea (e.g. for more than 3 days) following
   antibiotic treatment.
- patients who have a compromised immune system, are taking any immune modulators or
   have an autoimmune disorder.
- patients who are diabetic or take any blood pressure medication.
- patients who have any known allergies to the probiotics, or the herbs and bacteria used in
  the postbiotic formula.
- patients who are pregnant or nursing.
- 369

The double-blind randomization scheme for this study was as follows. Patients were given an 370 371 unmarked box (the study kit) containing stool sample materials, and either control or treatment 372 materials neither of which were marked. To blind study coordinators, boxes had been shuffled 373 after assembly of all study kits, prior to the study. Kits contained barcodes that allowed 374 identification of participants' treatment arm after the participant handed over their samples. One 375 of the subjects evaluated for participation was ineligible due to not meeting the inclusion criteria. Fifty subjects received the study kits. Seventeen subjects withdrew consent during follow-up; six 376 and twelve subjects from the control and the treatment arm, respectively, without explanation. 377 One patient from the treatment arm was removed from the study due to a second antibiotic 378 prescription which was not declared during enrolment. 379

380 Treatment regimens were as follows. In their study kit, the control arm received a 381 commercially available probiotic in unmarked capsules and a resistant starch placebo in an 382 unmarked capsule; the treatment arm received the same commercially available probiotic in 383 unmarked capsules and the fermentation-derived postbiotic in unmarked capsules. Subjects were 384 instructed to take one capsule of each every day during their antibiotic course and for ten days 385 after finishing the antibiotic course.

Patients were given a phone number to call to report any side effects; no such phone calls were received. Prior to the collection of each stool sample, study coordinators were checking in with patients via text message to remind them of the sample collection and ask for side effects, collectively presented in **Table 2**. Patients were contacted on study days 1,2,3,4 and 10, and there were no grade 3 or higher side effects reported.

### 392 Eligibility criteria, ethical approval, and consent to participate

- This study protocol was approved by the institutional review board (IRB) number: 120180088, 393 394 trial registration ID: ISRCTN30327931. Otherwise healthy ambulatory adult patients (Table 1) presenting to a clinic in Houston, Texas, between 05 and 06/2018 for non-gastrointestinal 395 infections were recruited. Participants were recruited by physicians. Onsite nurses, trained in 396 human subject research, reviewed the consent form with the potential participants and answered 397 any questions about the study and its potential risks. Informed consent was obtained from all 398 participants. Participants were compensated with a \$15 Amazon gift card per sample collected at 399 the end of the study. If a participant did not complete the study, they were not penalized and 400 rewarded for the samples they collected. 401
- 402

#### 403 Sample collection

After informed consent was obtained, participants were provided with 5 Diversigen OmniGene
Gut kits for stool collection at home, a kit which stabilized samples at room temperature for up to
60 days. Patient were handed a work sheet listing their expected samples, recorded the date of
sample collection, and shipped all samples in one batch. Samples were received and processed
by a specialized contract research organization, Diversigen, (Houston, Texas).

409

### 410 *Postbiotic composition*

Component	Quantity in a Capsule	Function
Ashwagandha root ( <i>Withania somnifera</i> ) extract	139.75 mg	Active Ingredient: Co- fermented herb with <i>Lactobacillus</i> and <i>Bifidobacterium</i>
Elderberry fruit ( <i>Sambucus nigra</i> ) powder	143 mg	Active Ingredient: Co- fermented herb with <i>Lactobacillus</i> and <i>Bifidobacterium</i>
Astragalus root (Astragalus membranaceus)	139.75 mg	Active Ingredient: Co- fermented herb with <i>Lactobacillus</i> and <i>Bifidobacterium</i>
Red lentils	227.5 mg	Bulking agent, nitrogen source

#### 411 DNA extraction and bacterial 16S rRNA gene sequencing

- 412 DNA from human samples was extracted with PowerSoil Pro (Qiagen) on the QiaCube HT
- 413 (Qiagen), using Powerbead Pro (Qiagen) plates with 0.5mm and 0.1mm ceramic beads. All PCR
- 414 products were analyzed with the Agilent TapeStation for quality control and then pooled
- 415 equimolar and sequenced directly in the Illumina MiSeq platform using the 2x250 bp protocol.
- 416 Human samples were prepared with a protocol derived from 44, using KAPA HiFi Polymerase
- 417 to amplify the V4 region of the 16S rRNA gene. Libraries were sequenced on an Illumina MiSeq
- using paired-end 2x250 reads and the MiSeq Reagent Kitv2. Sample processing and sequencing
  were performed by Diversigen.
- 420

# 421 Bioinformatic processing and taxonomic assignment

- 422 OTU tables were generated by Diversigen bioinformatics pipelines (detailed bioinformatic tools
- 423 and settings in **Supplementary Methods**). Briefly, Useach v7.0 was used to process raw
- sequencing reads, and taxonomy was assigned via the Silva database v128.
- 425

#### 426 Statistical analyses

427 Unless otherwise stated, statistical analyses were performed with Python 3, version 3.10.4 and R,
428 version 4.2.

We calculated the inverse Simpson (IVS) index from relative ASV abundances (p) with NASVs in a given sample,  $IVS = \frac{1}{\sum_{i}^{N} p_{i}^{2}}$ . Regression analyses were conducted using the statsmodels package for the Python programming language, using the functions *ols* and *mixedlm* for ordinary least squares and mixed effects modeling, respectively. Relevant code of primary analyses and corresponding data tables are available in the supplementary materials.

To account for compositionality of the relative abundance data, we performed a centered 434 log-ratio (CLR) transformations at different taxonomic aggregation levels, i.e. separate CLR for 435 genus, family, and phylum abundances. While this does not remove compositionality related data 436 437 analysis challenges, CLR transformations are increasingly used to reduce negative covariance biases in microbiome data. Regression models were implemented using the statsmodels (using 438 functions *ols* and *mixedlm*)<sup>76</sup> and penalized multiple variate regression models using the sklearn 439 packages (using the function *LogisticRegression*)<sup>77</sup> for the Python programming language, and 440 using the *nlme*<sup>78</sup> and *vegan*<sup>79</sup> library in R. 441

- 442 p values were adjusted as appropriate. A p-value <0.05 was considered significant after 443 adjustment for multiple comparisons where appropriate. Unless otherwise stated, significance 444 values are noted as follows: \* p < 0.05, \*\* p < 0.01, \*\*\* p < 0.001.
- Figure 1: Significance of differences in IVS were calculated using a mixed effects model for repeated measures with time treated as a categorical variable<sup>38,75</sup>; significance between arms at individual timepoints was determined using two-sided t-tests.
- Figure 2: Differences in sample-by-sample distances were calculated with the adonis2function from the vegan library for the R programming language.

Figure 3: Single time points were analyzed with univariate linear models using the *ols* function of the statsmodels package, multiple hypothesis correction was performed with the Benjamin/Hochberg procedure using the fdrcorrection function of the statsmodels.stats.multitest library for the Python programming language. The multivariate analysis of significant hits from the univariate screen was performed with the LogisticRegressionCV class from the scikit-learn package for the Python programming language.

#### 457 Data availability

458 Data, statistical test results, and relevant code to reproduce main analyses are available as

459 supplementary materials. The 16S rRNA gene sequencing results are available as supplementary

data files (Table S3). Raw sequencing reads are available on the sequencing read archive,

461 submission SUB13922145.

#### 462 Figures



463 464

# 465 Figure 1: Postbiotics significantly increased bacterial alpha diversity at the end of an

466 **antibiotic course.** A) Sample collection protocol and study design; primary endpoint of the trial

467 was alpha-diversity (inverse Simpson index) during the end of the antibiotic course (S1-S3),

additional endpoints were alpha-diversity (inverse Simpson) at later time points (S4, S5). **B**)

- 469 Enrolment and sample collection efficiency in percent of planned vs obtained; Full Analysis Set,
- 470 (FAS): 100%=16 samples per arm; cohort report in Figure S1. C) Alpha diversity directly after
- 471 finishing the antibiotic course (S2, p-values from two-sided t-tests). **D**) Inverse Simpson alpha
- diversity across timepoints S1-S3 was significantly higher in treated (purple) than control (grey)
- patients, see also Figure S2; p-value from linear mixed effects model<sup>38</sup>.
- ....
- 475
- 476
- 477









# 502 Supplementary Material

503

## 504 **Table S1:** Antibiotic exposures by treatment arm

505

Treatment	Antibiotic	
Т	Amoxicillin / Clavulanic acid	5
	Amoxicillin	2
	Amoxicillin / Clavulanic acid & Cefalexin	1
	Azithromycin	1
	Cefalexin	1
	Cefalexin / Trimethoprim / Sulfamethoxazole	1
	Ciprofloxacin	1
	Ciprofloxacin / Metronidazole	1
	Clindamycin	1
	Levofloxacin	1
	Penicillin	1
2	Amoxicillin / Clavulanic acid	7
	Amoxicillin	2
	Ciproflaxin / Metronidazole	1
	Ciprofloxacin	1
	Ciprofloxacin	1
	Clindamycin	1
	Trimethoprim / Sulfamethoxazole / Cefalexin	1
	Azithromycin	1
	Amoxicillin / Clavulanic acid & Clindamycin	1

# 506

507

## 508 Table S2: Reported adverse events

509

	Adverse Events	Severity	Related to Study	
Control	Rash	Mild	Unlikely related to control material	
	Diarrhea	Mild	Possibly related to control material	
	Bloating	Mild	Possibly related to control material	
Treatment	None reported			

510

# 511 Table S3: Data and statistical model output.

512 Supplementary file "Table S3 Data and Statistics.xlsx"

# 513 Supplementary Figures

514



515

516 Figure S1: CONSORT Report chart.



518 519

520 Figure S2: Higher alpha diversity observed across individual patients during primary

621 endpoints (S1-S3). Inverse Simpson alpha diversity in 32 patients (Control: PC, Treated: PT) at

522 the end of an antibiotic course across samples S1, S2, S3; patients sorted by trial arm and

523 average diversity in descending order from top left to bottom right. Dashed lines indicate control

- 524 (grey) and treated (red) patient averages.
- 525
- 526





- Figure S3: Relative abundances of probiotic genera. Relative genus abundances shown for samples from control (grey) and treated (purple) patients; differences were non-significant at 531 532 each time point between treatment arms (Wilcoxon rank sum tests).
- 533





Figure S4: CLR transformed relative abundances of five most strongly associated genera
across patients and time. Genera are organized in rows. A) CLR transformed relative
abundances by treatment arm at timepoint S2 alone, B) for each patient in timepoints S1, S2, and
S3 (dashed lines indicate medians per treatment arm), C) by treatment arm in timepoints S1, S2,
and S3.





542 **confirm univariate results.** Coefficient estimates from L1-penalized logistic regressions on

543 performed on CLR-transformed genus relative abundances in Sample S2 (A), or samples S1-S3

544 (**B**), at different regularization strengths up until all coefficients were set to zero (C: inverse

545 regularization strength).

546

A Sample S2	B	Sample S1-3
-5 - 1 - 1 - 1		
-s - <u>o</u> - <u>o</u>		
	╓	
	,	
-5		-5 Lachrospiraceae_NKKA156_group
-5•••		
-5		
0		
	<u>ر</u>	

- 548 Figure S6: Relative abundance of bacterial families and genera, sorted by average abundance.
- 549 Log-10 transformed relative family abundances in sample S2 (A) and genus (B) abundances
- 550 pooled over samples S1-S3 in treated (T) and control (C) patients. Boxes highlight select taxa
- discussed as modulating cancer immunotherapies<sup>31,32,35</sup>. \*\*\*: p<0.001, \*\*: p<0.01, \*: p<0.05, .:
- 552 p<0.1, n.s.: p>0.1; non-parametric Wilcoxon rank sums test not corrected for multiple
- 553 hypotheses.



555







# 566 patients who received a postbiotic during their treatment and becomes similar ten days

567 after finishing the antibiotic. Thick lines show a locally weighted scatterplot smoothing curve

568 for treated (purple) and control (grey) patients' bacterial alpha diversity across five

569 longitudinally collected samples; dashed lines and shaded regions show mean and confidence

570 intervals of a second-order line fit with time in days as predictor of alpha diversity.

#### 572 **Bibliography**

- Havey, T.C., Fowler, R.A., and Daneman, N. (2011). Duration of antibiotic therapy for
   bacteremia: a systematic review and meta-analysis. Crit Care 15, R267. 10.1186/cc10545.
- 575 2. Hutchings, M.I., Truman, A.W., and Wilkinson, B. (2019). Antibiotics: past, present and
  576 future. Curr Opin Microbiol *51*, 72–80. 10.1016/j.mib.2019.10.008.
- Maier, L., Goemans, C.V., Wirbel, J., Kuhn, M., Eberl, C., Pruteanu, M., Müller, P., GarciaSantamarina, S., Cacace, E., Zhang, B., et al. (2021). Unravelling the collateral damage of
  antibiotics on gut bacteria. Nature *599*, 120–124. 10.1038/s41586-021-03986-2.
- Blaser, M.J. (2016). Antibiotic use and its consequences for the normal microbiome. Science 352, 544–545. 10.1126/science.aad9358.
- 5. Modi, S.R., Collins, J.J., and Relman, D.A. (2014). Antibiotics and the gut microbiota. J Clin
  Invest *124*, 4212–4218. 10.1172/JCI72333.
- 6. Whangbo, J., Ritz, J., and Bhatt, A. (2017). Antibiotic-mediated modification of the
  intestinal microbiome in allogeneic hematopoietic stem cell transplantation. Bone Marrow
  Transplant 52, 183–190. 10.1038/bmt.2016.206.
- 587 7. Dethlefsen, L., and Relman, D.A. (2011). Incomplete recovery and individualized responses
  588 of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci
  589 USA *108 Suppl 1*, 4554–4561. 10.1073/pnas.1000087107.
- Niehus, R., van Kleef, E., Mo, Y., Turlej-Rogacka, A., Lammens, C., Carmeli, Y., Goossens,
   H., Tacconelli, E., Carevic, B., Preotescu, L., et al. (2020). Quantifying antibiotic impact on
   within-patient dynamics of extended-spectrum beta-lactamase resistance. Elife 9, e49206.
   10.7554/eLife.49206.
- Morjaria, S., Schluter, J., Taylor, B.P., Littmann, E.R., Carter, R.A., Fontana, E., Peled, J.U.,
   van den Brink, M.R.M., Xavier, J.B., and Taur, Y. (2019). Antibiotic-Induced Shifts in Fecal
   Microbiota Density and Composition during Hematopoietic Stem Cell Transplantation.
   Infect Immun 87. 10.1128/IAI.00206-19.
- 10. Bernard-Raichon, L., Venzon, M., Klein, J., Axelrad, J.E., Zhang, C., Sullivan, A.P., Hussey,
  G.A., Casanovas-Massana, A., Noval, M.G., Valero-Jimenez, A.M., et al. (2022). Gut
  microbiome dysbiosis in antibiotic-treated COVID-19 patients is associated with microbial
  translocation and bacteremia. Nat Commun *13*, 5926. 10.1038/s41467-022-33395-6.
- 11. Schluter, J., Djukovic, A., Taylor, B.P., Yan, J., Duan, C., Hussey, G.A., Liao, C., Sharma,
  S., Fontana, E., Amoretti, L.A., et al. (2023). The TaxUMAP atlas: Efficient display of large
  clinical microbiome data reveals ecological competition in protection against bacteremia.
  Cell Host & Microbe. 10.1016/j.chom.2023.05.027.
- Palleja, A., Mikkelsen, K.H., Forslund, S.K., Kashani, A., Allin, K.H., Nielsen, T., Hansen,
  T.H., Liang, S., Feng, Q., Zhang, C., et al. (2018). Recovery of gut microbiota of healthy

- adults following antibiotic exposure. Nat Microbiol *3*, 1255–1265. 10.1038/s41564-018 0257-9.
- Brandt, L.J., Aroniadis, O.C., Mellow, M., Kanatzar, A., Kelly, C., Park, T., Stollman, N.,
  Rohlke, F., and Surawicz, C. (2012). Long-term follow-up of colonoscopic fecal microbiota
  transplant for recurrent Clostridium difficile infection. Am J Gastroenterol *107*, 1079–1087.
  10.1038/ajg.2012.60.
- Buffie, C.G., Bucci, V., Stein, R.R., McKenney, P.T., Ling, L., Gobourne, A., No, D., Liu,
  H., Kinnebrew, M., Viale, A., et al. (2015). Precision microbiome reconstitution restores bile
  acid mediated resistance to Clostridium difficile. Nature *517*, 205–208. 10.1038/nature13828.
- 15. Zhai, B., Ola, M., Rolling, T., Tosini, N.L., Joshowitz, S., Littmann, E.R., Amoretti, L.A.,
  Fontana, E., Wright, R.J., Miranda, E., et al. (2020). High-resolution mycobiota analysis
  reveals dynamic intestinal translocation preceding invasive candidiasis. Nat Med *26*, 59–64.
  10.1038/s41591-019-0709-7.
- 16. Willis, A.D. (2019). Rarefaction, Alpha Diversity, and Statistics. Front Microbiol *10*, 2407.
  10.3389/fmicb.2019.02407.
- 17. Kers, J.G., and Saccenti, E. (2021). The power of microbiome studies: some considerations
  on which alpha and beta metrics to use and how to report results. Front Microbiol *12*, 796025.
  10.3389/fmicb.2021.796025.
- 18. Peled, J.U., Gomes, A.L.C., Devlin, S.M., Littmann, E.R., Taur, Y., Sung, A.D., Weber, D.,
  Hashimoto, D., Slingerland, A.E., Slingerland, J.B., et al. (2020). Microbiota as Predictor of
  Mortality in Allogeneic Hematopoietic-Cell Transplantation. N Engl J Med *382*, 822–834.
  10.1056/NEJMoa1900623.
- 19. Taur, Y., Jenq, R.R., Perales, M.-A., Littmann, E.R., Morjaria, S., Ling, L., No, D.,
  Gobourne, A., Viale, A., Dahi, P.B., et al. (2014). The effects of intestinal tract bacterial
  diversity on mortality following allogeneic hematopoietic stem cell transplantation. Blood *124*, 1174–1182. 10.1182/blood-2014-02-554725.
- 634 20. Galloway-Peña, J.R., Smith, D.P., Sahasrabhojane, P., Ajami, N.J., Wadsworth, W.D., Daver,
  635 N.G., Chemaly, R.F., Marsh, L., Ghantoji, S.S., Pemmaraju, N., et al. (2016). The role of the
  636 gastrointestinal microbiome in infectious complications during induction chemotherapy for
  637 acute myeloid leukemia. Cancer *122*, 2186–2196. 10.1002/cncr.30039.
- Taur, Y., Xavier, J.B., Lipuma, L., Ubeda, C., Goldberg, J., Gobourne, A., Lee, Y.J., Dubin,
  K.A., Socci, N.D., Viale, A., et al. (2012). Intestinal domination and the risk of bacteremia in
  patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 55,
  905–914. 10.1093/cid/cis580.
- Faye, A.S., Allin, K.H., Iversen, A.T., Agrawal, M., Faith, J., Colombel, J.-F., and Jess, T.
  (2023). Antibiotic use as a risk factor for inflammatory bowel disease across the ages: a
  population-based cohort study. Gut *72*, 663–670. 10.1136/gutjnl-2022-327845.

- 23. Wang, Q., Zhang, S.-X., Chang, M.-J., Qiao, J., Wang, C.-H., Li, X.-F., Yu, Q., and He, P.-F.
  (2022). Characteristics of the Gut Microbiome and Its Relationship With Peripheral CD4+ T
  Cell Subpopulations and Cytokines in Rheumatoid Arthritis. Front Microbiol *13*, 799602.
  10.3389/fmicb.2022.799602.
- Björkstén, B., Sepp, E., Julge, K., Voor, T., and Mikelsaar, M. (2001). Allergy development
  and the intestinal microflora during the first year of life. J Allergy Clin Immunol *108*, 516–
  520. 10.1067/mai.2001.118130.
- Azad, M.B., Bridgman, S.L., Becker, A.B., and Kozyrskyj, A.L. (2014). Infant antibiotic
  exposure and the development of childhood overweight and central adiposity. Int J Obes
  (Lond) *38*, 1290–1298. 10.1038/ijo.2014.119.
- 26. Clemente, J.C., Manasson, J., and Scher, J.U. (2018). The role of the gut microbiome in
  systemic inflammatory disease. BMJ *360*, j5145. 10.1136/bmj.j5145.
- Sultan, A.A., Mallen, C., Muller, S., Hider, S., Scott, I., Helliwell, T., and Hall, L.J. (2019).
  Antibiotic use and the risk of rheumatoid arthritis: a population-based case-control study.
  BMC Medicine *17*, 154. 10.1186/s12916-019-1394-6.
- 28. Rao, C., Coyte, K.Z., Bainter, W., Geha, R.S., Martin, C.R., and Rakoff-Nahoum, S. (2021).
  Multi-kingdom ecological drivers of microbiota assembly in preterm infants. Nature *591*,
  633–638. 10.1038/s41586-021-03241-8.
- 29. Tomczak, H., Szałek, E., and Grześkowiak, E. (2014). The problems of urinary tract
  infections with Candida spp. aetiology in women. Postepy Hig Med Dosw (Online) 68,
  1036–1039. 10.5604/17322693.1118989.
- Smith, M., Dai, A., Ghilardi, G., Amelsberg, K.V., Devlin, S.M., Pajarillo, R., Slingerland,
  J.B., Beghi, S., Herrera, P.S., Giardina, P., et al. (2022). Gut microbiome correlates of
  response and toxicity following anti-CD19 CAR T cell therapy. Nat Med 28, 713–723.
  10.1038/s41591-022-01702-9.
- Gopalakrishnan, V., Spencer, C.N., Nezi, L., Reuben, A., Andrews, M.C., Karpinets, T.V.,
  Prieto, P.A., Vicente, D., Hoffman, K., Wei, S.C., et al. (2018). Gut microbiome modulates
  response to anti-PD-1 immunotherapy in melanoma patients. Science *359*, 97–103.
  10.1126/science.aan4236.
- 874 32. Routy, B., Le Chatelier, E., Derosa, L., Duong, C.P.M., Alou, M.T., Daillère, R., Fluckiger,
  875 A., Messaoudene, M., Rauber, C., Roberti, M.P., et al. (2018). Gut microbiome influences
  876 efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359, 91–97.
  877 10.1126/science.aan3706.
- 33. Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J.J., and
  Gajewski, T.F. (2018). The commensal microbiome is associated with anti-PD-1 efficacy in
  metastatic melanoma patients. Science *359*, 104–108. 10.1126/science.aao3290.

- 34. Hu, Y., Li, J., Ni, F., Yang, Z., Gui, X., Bao, Z., Zhao, H., Wei, G., Wang, Y., Zhang, M., et
  al. (2022). CAR-T cell therapy-related cytokine release syndrome and therapeutic response is
  modulated by the gut microbiome in hematologic malignancies. Nat Commun *13*, 5313.
  10.1038/s41467-022-32960-3.
- Schluter, J., Peled, J.U., Taylor, B.P., Markey, K.A., Smith, M., Taur, Y., Niehus, R., Staffas,
  A., Dai, A., Fontana, E., et al. (2020). The gut microbiota is associated with immune cell
  dynamics in humans. Nature *588*, 303–307. 10.1038/s41586-020-2971-8.
- 36. Olin, A., Henckel, E., Chen, Y., Lakshmikanth, T., Pou, C., Mikes, J., Gustafsson, A.,
  Bernhardsson, A.K., Zhang, C., Bohlin, K., et al. (2018). Stereotypic immune system
  development in newborn children. Cell *174*, 1277-1292.e14. 10.1016/j.cell.2018.06.045.
- 37. Wastyk, H.C., Fragiadakis, G.K., Perelman, D., Dahan, D., Merrill, B.D., Yu, F.B., Topf, M.,
  Gonzalez, C.G., Van Treuren, W., Han, S., et al. (2021). Gut-microbiota-targeted diets
  modulate human immune status. Cell *184*, 4137-4153 e14. 10.1016/j.cell.2021.06.019.
- 38. Taur, Y., Coyte, K., Schluter, J., Robilotti, E., Figueroa, C., Gjonbalaj, M., Littmann, E.R.,
  Ling, L., Miller, L., Gyaltshen, Y., et al. (2018). Reconstitution of the gut microbiota of
  antibiotic-treated patients by autologous fecal microbiota transplant. Sci Transl Med *10*.
  10.1126/scitranslmed.aap9489.
- 39. Costello, S.P., Hughes, P.A., Waters, O., Bryant, R.V., Vincent, A.D., Blatchford, P.,
  Katsikeros, R., Makanyanga, J., Campaniello, M.A., Mavrangelos, C., et al. (2019). Effect of
  Fecal Microbiota Transplantation on 8-Week Remission in Patients With Ulcerative Colitis.
  JAMA 321, 156–164. 10.1001/jama.2018.20046.
- 40. Davar, D., Dzutsev, A.K., McCulloch, J.A., Rodrigues, R.R., Chauvin, J.-M., Morrison,
  R.M., Deblasio, R.N., Menna, C., Ding, Q., Pagliano, O., et al. (2021). Fecal microbiota
  transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science *371*,
  595–602. 10.1126/science.abf3363.
- 41. Bakken, J.S., Polgreen, P.M., Beekmann, S.E., Riedo, F.X., and Streit, J.A. (2013).
  Treatment approaches including fecal microbiota transplantation for recurrent Clostridium difficile infection (RCDI) among infectious disease physicians. Anaerobe *24*, 20–24.
  10.1016/j.anaerobe.2013.08.007.
- 42. van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E.G., de Vos, W.M.,
  Visser, C.E., Kuijper, E.J., Bartelsman, J.F.W.M., Tijssen, J.G.P., et al. (2013). Duodenal
  infusion of donor feces for recurrent Clostridium difficile. N Engl J Med *368*, 407–415.
  10.1056/NEJMoa1205037.
- 43. Sandhu, A., and Chopra, T. (2021). Fecal microbiota transplantation for recurrent
  Clostridioides difficile, safety, and pitfalls. Therap Adv Gastroenterol *14*,
  17562848211053105. 10.1177/17562848211053105.
- 44. DeFilipp, Z., Bloom, P.P., Torres Soto, M., Mansour, M.K., Sater, M.R.A., Huntley, M.H.,
  Turbett, S., Chung, R.T., Chen, Y.-B., and Hohmann, E.L. (2019). Drug-Resistant E. coli

- Bacteremia Transmitted by Fecal Microbiota Transplant. N Engl J Med *381*, 2043–2050.
  10.1056/NEJMoa1910437.
- 45. Ianiro, G., Punčochář, M., Karcher, N., Porcari, S., Armanini, F., Asnicar, F., Beghini, F.,
  Blanco-Míguez, A., Cumbo, F., Manghi, P., et al. (2022). Variability of strain engraftment
  and predictability of microbiome composition after fecal microbiota transplantation across
  different diseases. Nat Med *28*, 1913–1923. 10.1038/s41591-022-01964-3.
- 46. Commissioner, O. of the (2022). FDA Approves First Fecal Microbiota Product. FDA.
   https://www.fda.gov/news-events/press-announcements/fda-approves-first-fecal-microbiota product.
- 47. Commissioner, O. of the (2023). FDA Approves First Orally Administered Fecal Microbiota
  Product for the Prevention of Recurrence of Clostridioides difficile Infection. FDA.
  https://www.fda.gov/news-events/press-announcements/fda-approves-first-orallyadministered-fecal-microbiota-product-prevention-recurrence-clostridioides.
- 48. Suez, J., Zmora, N., Segal, E., and Elinav, E. (2019). The pros, cons, and many unknowns of
   probiotics. Nat Med 25, 716–729. 10.1038/s41591-019-0439-x.
- 49. Besselink, M.G., Santvoort, H.C. van, Buskens, E., Boermeester, M.A., Goor, H. van,
  Timmerman, H.M., Nieuwenhuijs, V.B., Bollen, T.L., Ramshorst, B. van, Witteman, B.J., et
  al. (2008). Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised,
  double-blind, placebo-controlled trial. The Lancet *371*, 651–659. 10.1016/S01406736(08)60207-X.
- 50. Zmora, N., Zilberman-Schapira, G., Suez, J., Mor, U., Dori-Bachash, M., Bashiardes, S.,
  Kotler, E., Zur, M., Regev-Lehavi, D., Brik, R.B.-Z., et al. (2018). Personalized Gut Mucosal
  Colonization Resistance to Empiric Probiotics Is Associated with Unique Host and
  Microbiome Features. Cell *174*, 1388-1405.e21. 10.1016/j.cell.2018.08.041.
- 51. Zhang, C., Derrien, M., Levenez, F., Brazeilles, R., Ballal, S.A., Kim, J., Degivry, M.-C.,
  Quéré, G., Garault, P., van Hylckama Vlieg, J.E.T., et al. (2016). Ecological robustness of
  the gut microbiota in response to ingestion of transient food-borne microbes. ISME J *10*,
  2235–2245. 10.1038/ismej.2016.13.
- 52. Salminen, M.K., Rautelin, H., Tynkkynen, S., Poussa, T., Saxelin, M., Valtonen, V., and
  Järvinen, A. (2004). Lactobacillus Bacteremia, Clinical Significance, and Patient Outcome,
  with Special Focus on Probiotic L. Rhamnosus GG. Clin Infect Dis *38*, 62–69.
  10.1086/380455.
- 53. Cassone, M., Serra, P., Mondello, F., Girolamo, A., Scafetti, S., Pistella, E., and Venditti, M.
  (2003). Outbreak of Saccharomyces cerevisiae Subtype boulardii Fungemia in Patients
  Neighboring Those Treated with a Probiotic Preparation of the Organism. Journal of Clinical
  Microbiology. 10.1128/jcm.41.11.5340-5343.2003.
- 54. Suez, J., Zmora, N., Zilberman-Schapira, G., Mor, U., Dori-Bachash, M., Bashiardes, S., Zur,
   M., Regev-Lehavi, D., Brik, R.B.-Z., Federici, S., et al. (2018). Post-Antibiotic Gut Mucosal

- Microbiome Reconstitution Is Impaired by Probiotics and Improved by Autologous FMT.
  Cell *174*, 1406-1423.e16. 10.1016/j.cell.2018.08.047.
- 55. Salminen, S., Collado, M.C., Endo, A., Hill, C., Lebeer, S., Quigley, E.M.M., Sanders, M.E.,
  Shamir, R., Swann, J.R., Szajewska, H., et al. (2021). The International Scientific
  Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and
  scope of postbiotics. Nat Rev Gastroenterol Hepatol *18*, 649–667. 10.1038/s41575-02100440-6.
- 56. Zhou, X., Qi, W., Hong, T., Xiong, T., Gong, D., Xie, M., and Nie, S. (2018).
  Exopolysaccharides from Lactobacillus plantarum NCU116 Regulate Intestinal Barrier
  Function via STAT3 Signaling Pathway. J Agric Food Chem *66*, 9719–9727.
  10.1021/acs.jafc.8b03340.
- 57. Mosca, A., Abreu Y Abreu, A.T., Gwee, K.A., Ianiro, G., Tack, J., Nguyen, T.V.H., and Hill,
  C. (2022). The clinical evidence for postbiotics as microbial therapeutics. Gut Microbes *14*,
  2117508. 10.1080/19490976.2022.2117508.
- 58. Stein-Thoeringer, C.K., Saini, N.Y., Zamir, E., Blumenberg, V., Schubert, M.-L., Mor, U.,
  Fante, M.A., Schmidt, S., Hayase, E., Hayase, T., et al. (2023). A non-antibiotic-disrupted
  gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer
  immunotherapy. Nat Med *29*, 906–916. 10.1038/s41591-023-02234-6.
- 59. Schulz, K.F., Altman, D.G., Moher, D., and CONSORT Group (2010). CONSORT 2010
  statement: updated guidelines for reporting parallel group randomised trials. BMJ *340*, c332.
  10.1136/bmj.c332.
- 60. Barbut, F., and Meynard, J.L. (2002). Managing antibiotic associated diarrhoea. BMJ *324*, 1345–1346.
- 61. Hensgens, M.P.M., Goorhuis, A., Dekkers, O.M., and Kuijper, E.J. (2012). Time interval of
  increased risk for Clostridium difficile infection after exposure to antibiotics. J Antimicrob
  Chemother 67, 742–748. 10.1093/jac/dkr508.
- 62. Wilton, L., Kollarova, M., Heeley, E., and Shakir, S. (2003). Relative risk of vaginal
  candidiasis after use of antibiotics compared with antidepressants in women: postmarketing
  surveillance data in England. Drug Saf 26, 589–597. 10.2165/00002018-200326080-00005.
- 63. Yu, D., Du, J., Pu, X., Zheng, L., Chen, S., Wang, N., Li, J., Chen, S., Pan, S., and Shen, B.
  (2022). The Gut Microbiome and Metabolites Are Altered and Interrelated in Patients With
  Rheumatoid Arthritis. Front Cell Infect Microbiol *11*, 763507. 10.3389/fcimb.2021.763507.
- 64. Nie, K., Ma, K., Luo, W., Shen, Z., Yang, Z., Xiao, M., Tong, T., Yang, Y., and Wang, X.
  (2021). Roseburia intestinalis: A Beneficial Gut Organism From the Discoveries in Genus and Species. Front Cell Infect Microbiol *11*, 757718. 10.3389/fcimb.2021.757718.
- 65. Bui, T.P.N., Mannerås-Holm, L., Puschmann, R., Wu, H., Troise, A.D., Nijsse, B., Boeren,
  S., Bäckhed, F., Fiedler, D., and deVos, W.M. (2021). Conversion of dietary inositol into

propionate and acetate by commensal Anaerostipes associates with host health. Nat Commun *12*, 4798. 10.1038/s41467-021-25081-w.

- 66. Freier, T.A., Beitz, D.C., Li, L., and Hartman, P.A. (1994). Characterization of Eubacterium
  coprostanoligenes sp. nov., a cholesterol-reducing anaerobe. Int J Syst Bacteriol *44*, 137–142.
  10.1099/00207713-44-1-137.
- 67. Mima, K., Sukawa, Y., Nishihara, R., Qian, Z.R., Yamauchi, M., Inamura, K., Kim, S.A.,
  Masuda, A., Nowak, J.A., Nosho, K., et al. (2015). Fusobacterium nucleatum and T Cells in
  Colorectal Carcinoma. JAMA Oncol 1, 653–661. 10.1001/jamaoncol.2015.1377.
- 68. Brennan, C.A., and Garrett, W.S. (2019). Fusobacterium nucleatum symbiont, opportunist
  and oncobacterium. Nat Rev Microbiol 17, 156–166. 10.1038/s41579-018-0129-6.
- 69. Osbelt, L., Wende, M., Almási, É., Derksen, E., Muthukumarasamy, U., Lesker, T.R.,
  Galvez, E.J.C., Pils, M.C., Schalk, E., Chhatwal, P., et al. (2021). Klebsiella oxytoca causes
  colonization resistance against multidrug-resistant K. pneumoniae in the gut via cooperative
  carbohydrate competition. Cell Host Microbe. 10.1016/j.chom.2021.09.003.
- 70. Oliveira, R.A., Ng, K.M., Correia, M.B., Cabral, V., Shi, H., Sonnenburg, J.L., Huang, K.C.,
  and Xavier, K.B. (2020). Klebsiella michiganensis transmission enhances resistance to
  Enterobacteriaceae gut invasion by nutrition competition. Nat Microbiol *5*, 630–641.
  10.1038/s41564-019-0658-4.
- 812 71. Buffie, C.G., and Pamer, E.G. (2013). Microbiota-mediated colonization resistance against
  813 intestinal pathogens. Nat Rev Immunol *13*, 790–801. 10.1038/nri3535.
- Roswall, J., Olsson, L.M., Kovatcheva-Datchary, P., Nilsson, S., Tremaroli, V., Simon, M.C., Kiilerich, P., Akrami, R., Krämer, M., Uhlén, M., et al. (2021). Developmental trajectory
  of the healthy human gut microbiota during the first 5 years of life. Cell Host & Microbe 29,
  765-776.e3. 10.1016/j.chom.2021.02.021.
- 73. Vatanen, T., Franzosa, E.A., Schwager, R., Tripathi, S., Arthur, T.D., Vehik, K., Lernmark,
  Å., Hagopian, W.A., Rewers, M.J., She, J.-X., et al. (2018). The human gut microbiome in
  early-onset type 1 diabetes from the TEDDY study. Nature *562*, 589–594. 10.1038/s41586018-0620-2.
- 74. Coyte, K.Z., Schluter, J., and Foster, K.R. (2015). The ecology of the microbiome: Networks, competition, and stability. Science *350*, 663–666. 10.1126/science.aad2602.
- 824 75. Button, J.E., Cosetta, C.M., Reens, A.L., Brooker, S.L., Rowan-Nash, A.D., Lavin, R.C.,
  825 Saur, R., Zheng, S., Autran, C.A., Lee, M.L., et al. (2023). Precision modulation of dysbiotic
  826 adult microbiomes with a human-milk-derived synbiotic reshapes gut microbial composition
  827 and metabolites. Cell Host & Microbe. 10.1016/j.chom.2023.08.004.
- 828 76. Seabold, S., and Perktold, J. (2010). Statsmodels: Econometric and Statistical Modeling with
  829 Python. Proceedings of the 9th Python in Science Conference, 92–96. 10.25080/Majora830 92bf1922-011.

- 77. Pedregosa, F., Varoquaux, G., Gramfort, A., Michel, V., Thirion, B., Grisel, O., Blondel, M.,
  Prettenhofer, P., Weiss, R., Dubourg, V., et al. (2011). Scikit-learn: Machine Learning in
  Python. Journal of Machine Learning Research *12*, 2825–2830.
- 78. Pinheiro, J.C., Bates, D.M., DebRoy, S.S., and Sarkar, D. (2013). Nlme: Linear and
  Nonlinear Mixed Effects Models.
- 79. Oksanen, J., Simpson, G.L., Blanchet, F.G., Kindt, R., Legendre, P., Minchin, P.R., O'Hara,
  R.B., Solymos, P., Stevens, M.H.H., Szoecs, E., et al. (2022). vegan: Community Ecology
  Package.





Rikenellaceae\*

Alcaligenaceae

Veillonellaceae\*



Bifidobacteriaceae

Acidaminococcaceae\*

Pasteurellaceae

S1

S2

S3



Patient ID

Treatment

Control

•...•

